AAMDSIF is proud to announce the launch of our new website! You'll now find everything quickly and easily.
Our patients, families, and caregivers have been asking us for more ways to learn about rare blood cancers and bone marrow failure diseases. So, we're coming to you today, thanks to generous support from individual donors and our corporate partners.
Here is a discussion of the recent approval of Luspatercept with Dr. Amit Verma, Director of the Division of Hematologic Malignancies and a Professor of Oncology at the Albert Einstein College of Medicine in New York City. He explains the results of clinical trials and describes which MDS patients have the best response to this medication.
#MDS #treatingMDS
Dr. Gustavo Rivero describes strategies for the management of Low-Risk MDS, or Myelodysplastic Syndromes. He details supportive care for these patients, including transfusions and iron overload therapies.
Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.
Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.
Eliot's disease of Myelodysplastic Syndromes with IDH1 and IDH2 mutations developed quickly. His son was his donor for the haploidentical bone marrow transplant, and now he thrives thanks to a clinical trial drug that keeps the Acute Myeloid Leukemia and MDS in remission. Listen to his story now.
Dr. Ehab Atallah discusses the good news about treatment for MDS, Myelodysplastic Syndromes, for patients ages 65 and older.
Terri shares the journey of Thomas' surprise diagnosis, rigorous treatment, and wonderful survivorship in this conversation.
10 years after diagnosis, Leigh Ann needed a bone marrow transplant. Five years later, her son did, too! Listen to her story of different family members having the same rare disease, Myelodysplastic Syndromes, here.
Why would I choose a clinical trial? What kind of additional care would I receive? How do I know if I qualify?
Christina Cline, RN, BSN, CCRC, explains both patient and nurse navigator roles in this recent recording.
Mark had no symptoms prior to diagnosis. Even more surprising was the "watch and wait" treatment plan! Listen to this recently recorded episode where Mark describes living as an MDS survivor now.
Special thanks to Abbvie and Taiho Oncology